Author: Fiona Craig

Kendrick Resources (LSE:KEN) has unveiled the results of an initial evaluation of the Kieshöhe prospect within its Bonya Rare Earth District in Namibia, with management suggesting the target has the potential to become a major rare earth discovery alongside the company’s flagship Teufelskuppe project.

Kieshöhe comprises a large carbonatite system accompanied by mineralised dykes and has returned average total rare earth oxide (TREO) grades of 1.51% by weight. The mineralisation is dominated by light rare earth elements, including neodymium and praseodymium, which are widely used in high-performance magnets and clean energy technologies.

Drilling points to scale and continuity of mineralisation

According to the company, drilling and historical exploration data indicate extensive mineralisation throughout the prospect. Kendrick reported several high-grade intersections and noted that mineralisation appears continuous from surface to depth.

Importantly, all completed boreholes ended within mineralised carbonatite, suggesting the system remains open and may extend beyond the areas tested to date. Management believes this provides encouraging evidence that the prospect could host a substantial rare earth resource.

Company sees potential for world-class district

Kendrick stated that the combination of grade and scale places Kieshöhe among the more attractive hard-rock rare earth prospects when compared with similar projects globally. Management believes the asset could rank within the upper quartile of comparable developments based on currently available information.

When considered alongside the nearby Teufelskuppe project, the company sees the Bonya district as having the potential to evolve into a rare earth resource of significant global importance. The district-wide opportunity is expected to become a central focus of future exploration efforts.

Accelerated work programme planned

To further evaluate the prospect, Kendrick intends to accelerate drilling and resource modelling activities across the Bonya project area. The objective is to better define the extent of mineralisation and support the development of a formal resource estimate.

Management believes continued exploration success could strengthen the case for a large-scale critical minerals project in Namibia, a jurisdiction that is increasingly attracting attention from companies seeking exposure to strategic metals required for electrification and energy transition technologies.

Financial fundamentals remain a key challenge

Despite the encouraging exploration results, Kendrick’s outlook continues to be constrained by its financial position. The company remains pre-revenue and continues to report losses, negative cash flow and negative shareholder equity, reflecting the early-stage nature of its operations.

Technical indicators have been considerably more supportive, with strong momentum signals providing a positive backdrop for the shares. However, valuation remains difficult to assess due to the absence of earnings and the lack of a dividend, limiting the usefulness of traditional valuation metrics.

More about Kendrick Resources PLC

Kendrick Resources PLC is a mineral exploration and development company focused on identifying and advancing resource projects through exploration, technical evaluation and project development. The company’s management team has extensive experience in southern Africa, and its principal assets include the Bonya Rare Earth Project in Namibia and the Blue Fox licence area in northwestern Zambia. Kendrick is focused on commodities considered important to the global energy transition and future industrial demand.

Avacta Group (LSE:AVCT) has raised approximately £9 million through an oversubscribed equity placing, reinforcing its financial position and providing additional funding for the continued development of its oncology pipeline. The fundraising involved the issue of around 12.8 million new shares at 70 pence each and included a modest subscription from directors.

The company intends to use the proceeds to strengthen its balance sheet, including the repayment of deferred liabilities and an additional quarterly payment toward its convertible bond obligations.

Debt reduction expected to limit future dilution

Management said the fundraising will help reduce the potential dilution associated with the company’s convertible bond. If accelerated repayments are completed as planned, the outstanding balance of the bond could be reduced to approximately £11.5 million.

By lowering debt obligations and improving liquidity, Avacta aims to create greater financial flexibility while supporting the advancement of its clinical development programmes.

Extended runway supports oncology pipeline

The strengthened cash position is expected to extend the company’s funding runway and enable continued progress across its next-generation cancer therapies.

Avacta plans to advance its first- and second-generation oncology candidates through key clinical milestones while also progressing a third-generation molecule into investigational new drug (IND)-enabling studies. Management believes these programmes represent important opportunities to demonstrate the potential of the company’s proprietary technology platform.

Clinical data and partnership discussions in focus

Several upcoming milestones are expected to be significant for the business. Investors are awaiting further clinical data from AVA6000 and AVA6103, which could provide additional evidence supporting the effectiveness of the company’s approach to targeted cancer treatment.

At the same time, Avacta continues to hold partnership discussions covering all three generations of its pre|CISION platform. Successful collaborations could provide validation of the technology, broaden development opportunities and strengthen the company’s commercial prospects.

Management views both clinical progress and strategic partnerships as key drivers of future value creation and investor confidence.

Financial challenges remain despite stronger cash position

While the fundraising improves near-term financial flexibility, Avacta continues to face challenges associated with its clinical-stage business model. The company remains loss-making and continues to consume cash as it invests in research and development activities.

Technical indicators offer some support, with the share price trading above longer-term moving averages and momentum measures such as MACD remaining positive. However, valuation metrics remain constrained by negative earnings and the absence of a dividend.

Although recent clinical progress and improved cash management provide positive momentum, investors continue to monitor financing requirements, partnership outcomes and development timelines as important factors influencing the company’s future prospects.

More about Avacta Group plc

Avacta Group plc is a clinical-stage life sciences company focused on developing oncology treatments through its proprietary pre|CISION peptide drug conjugate platform. The technology is designed to activate cancer therapies selectively within tumours, with the aim of increasing treatment effectiveness while reducing systemic side effects. Through its pipeline of next-generation oncology candidates, the company is seeking to improve patient outcomes and expand the potential applications of targeted cancer therapies.

Forgent plc (LSE:FORG) has completed planning for its first drilling campaign at the Peak Hills gold-copper project in Western Australia, marking an important step forward in the development of its exploration portfolio. The company, which focuses on critical and precious metals opportunities linked to the energy transition, currently holds a majority interest in the project and retains the option to increase its ownership substantially.

Peak Hills covers approximately 163 square kilometres across a package of granted tenements and is viewed by management as a key asset within the company’s Australian growth strategy.

Aircore drilling programme set to begin in June

The initial exploration campaign will consist of around 42 aircore drill holes for a total of approximately 2,860 metres. Drilling is expected to commence on or around 21 June 2026 and continue for roughly three weeks.

The programme has been designed to evaluate a series of priority exploration targets identified through analysis of historical exploration data and previous mineralisation results. Management believes the campaign will provide valuable information to guide future exploration activities across the broader project area.

Seven priority targets selected for testing

The planned drilling will focus on seven high-priority target zones located within the Karalundi, Junction and Curley’s prospects. Objectives include confirming historic gold and copper mineralisation, assessing the potential for extensions to known mineralised areas and improving the company’s understanding of the project’s geological characteristics.

Results from the programme are expected to help refine future exploration priorities and identify areas that may warrant more extensive follow-up work.

Initial assay results are anticipated in early August 2026, providing the first significant drilling data generated by Forgent since acquiring its interest in the project.

Exploration milestone supports Australian expansion strategy

Management views the forthcoming drilling programme as a key operational milestone in advancing Peak Hills and strengthening the company’s presence in Western Australia. The campaign forms part of a broader strategy focused on identifying and developing critical and precious metals resources that could benefit from long-term demand trends linked to electrification and the global energy transition.

By leveraging historical exploration datasets alongside modern targeting techniques, Forgent aims to accelerate the evaluation of prospective areas across the project.

Financial pressures continue to weigh on outlook

Despite the operational progress, the company’s outlook remains constrained by ongoing financial challenges. Forgent continues to report losses, negative cash flow and leverage-related pressures, factors that remain central to the investment case.

Technical indicators also remain weak, with the shares continuing to trade within a longer-term downtrend. Valuation support is limited given the company’s negative earnings profile and the absence of a dividend.

More about Forgent plc

Forgent plc is a technology-led energy transition company focused on the exploration of critical and precious metals. Its primary assets are located in Western Australia, where it is targeting gold and copper opportunities. The company currently holds a 51% interest in the Peak Hills project, which spans approximately 163 square kilometres across five granted tenements, and has the option to increase its ownership stake to 99%.

Iofina plc (LSE:IOF) has entered into a new agreement with a brine water supplier that is expected to significantly increase production at its IO#11 iodine extraction plant in Central Oklahoma. The arrangement supports the company’s strategy of expanding iodine output while maximising the efficiency of its existing infrastructure.

The company, which specialises in iodine production and halogen-based specialty chemicals, operates a network of IOsorb® extraction facilities in Oklahoma and is currently extending its footprint into the Permian Basin.

Pipeline project expected to increase iodine production

As part of the agreement, Iofina will invest approximately US$1.5 million in a pipeline project being developed by its supply partner. Once completed, the infrastructure is expected to provide additional brine feedstock to the IO#11 facility, which commenced operations in July 2025.

Management estimates the increased supply could raise annual crystalline iodine production by between 45 and 65 tonnes, representing roughly a 50% increase in output from the plant. The expansion is expected to strengthen the facility’s long-term production profile and contribute to the company’s broader growth objectives.

Capital-efficient expansion with rapid payback potential

Under the terms of the arrangement, brine water will be transported to the IO#11 site for iodine extraction before being returned to the partner’s disposal facility. Construction of the pipeline system is scheduled for completion during the third quarter of 2026.

Iofina believes the project offers an attractive return profile due to its relatively modest capital requirements and potential for rapid payback. By increasing throughput at an existing facility, the company aims to enhance production capacity without the higher costs typically associated with building new plants.

Growth strategy extends beyond Oklahoma

The latest agreement comes as Iofina continues work on its first iodine extraction plant in the Permian Basin, a project intended to expand the company’s production footprint beyond Oklahoma. Management views both initiatives as complementary steps in its long-term strategy to increase output and strengthen its position within the global iodine market.

The company expects these investments to support future growth while helping meet demand for iodine and iodine-based specialty chemical products.

Strong fundamentals balanced by execution risks

Iofina’s outlook is supported by favourable financial metrics, including revenue growth, low leverage and a strong technical trading profile. Valuation measures also remain attractive, with the shares trading on a relatively low earnings multiple.

However, investors continue to monitor free cash flow volatility and the execution risks associated with the company’s ongoing capital investment programme. The success of planned expansion projects during 2026 and 2027 will be an important factor in determining whether management can deliver its anticipated growth targets.

More about Iofina plc

Iofina plc is a vertically integrated iodine producer and specialty chemicals manufacturer, ranking as the second-largest iodine producer in North America. Through its Iofina Resources and Iofina Chemical divisions, the company operates eight IOsorb® iodine extraction facilities in Oklahoma and is developing a ninth plant in the Permian Basin. In addition to iodine production, Iofina manufactures and supplies a range of halogen-based specialty chemical products to customers worldwide.

Genedrive plc (LSE:GDR) has received approximately £0.76 million from HMRC through the UK’s research and development tax credit programme, providing additional funding to support the continued development and commercial expansion of its point-of-care genetic testing platform.

The payment relates to the company’s financial years ended 30 June 2024 and 30 June 2025 and represents a non-dilutive source of capital that strengthens its financial position as it seeks to broaden adoption of its precision medicine technologies in the UK and overseas markets.

Funding supports expansion of pharmacogenetic testing

The Manchester-based diagnostics company focuses on rapid pharmacogenetic tests designed to enable more personalised prescribing decisions at the point of care. Management said the tax credit proceeds will bolster the balance sheet and provide further resources to support both product development and commercial growth initiatives.

Genedrive continues to target opportunities in emergency and acute healthcare settings, where rapid genetic testing can help clinicians make treatment decisions more quickly and improve patient outcomes.

NHS-backed products form foundation of growth strategy

The company has established a portfolio that includes two CE-IVD approved diagnostic assays that have also received recommendations from the National Institute for Health and Care Excellence (NICE).

One test is designed to identify stroke patients who may not respond effectively to the antiplatelet drug Clopidogrel, helping clinicians select more appropriate treatments. The second aims to reduce the risk of antibiotic-induced hearing loss in newborns by identifying patients with a genetic susceptibility before treatment begins.

By enabling more targeted prescribing decisions, the company believes its products can improve clinical outcomes while helping healthcare providers reduce costs and operational pressures.

Financial challenges remain despite positive operational progress

Although the latest tax credit payment provides additional financial flexibility, Genedrive’s outlook continues to be affected by ongoing losses, persistent cash burn and a declining equity base. These factors remain key considerations for investors despite the company maintaining relatively low levels of debt.

Technical indicators offer a more balanced picture, with the share price trading above major moving averages and momentum signals remaining broadly neutral. However, valuation support remains limited as the company continues to report negative earnings and does not currently offer a dividend.

More about Genedrive

Genedrive plc is a UK-based commercial-stage pharmacogenetic diagnostics company specialising in rapid point-of-care testing technologies. Its proprietary platform supports genetic assays designed to improve prescribing decisions in emergency and acute care settings. The company’s products include two CE-IVD approved and NICE-recommended tests currently used within the NHS, and it is focused on expanding the adoption of precision diagnostics both domestically and internationally.

Bluebird Mining Ventures (LSE:BMV) has reported its first complete month of revenue generation from operating assets, marking an important milestone in the company’s transition from building its investment portfolio to producing recurring cash flows. The achievement follows revenue contributions during May 2026 from the group’s Bitcoin- and precious-metals-related streaming activities.

Management said the business has benefited from the restructuring of legacy assets in Asia, strategic recruitment initiatives and efforts to strengthen the balance sheet, leaving the company in what it describes as its strongest financial position for several years.

Focus remains on growing streaming portfolio

The company continues to progress its flagship gold streaming opportunity, which management expects will become a central component of its long-term portfolio. Alongside this project, Bluebird is reviewing additional streaming and royalty transactions capable of generating cash flow over both the near and medium term.

The strategy is aimed at building a diversified portfolio of revenue-producing assets while increasing exposure to precious metals and other scarce monetary assets that management believes can support long-term shareholder value creation.

Treasury assets drive net asset value growth

Bluebird’s treasury holdings, which include exposure to both gold and Bitcoin, now account for 58.9% of the company’s total net asset value, estimated at approximately US$1.25 million. The company reported a substantial increase in NAV since the start of the year, reflecting the appreciation of treasury assets and the impact of its evolving investment strategy.

Management views its treasury approach as a key element of the business model, using allocations to gold and digital assets to complement cash-generating streaming investments and strengthen the company’s overall financial position.

Financial and technical indicators remain challenging

Despite the operational progress reported, the company’s broader outlook remains constrained by its financial profile. Bluebird continues to report operating losses and negative cash flow, while revenue generation remains at an early stage. Balance-sheet leverage metrics provide some support, but have yet to fully offset these challenges.

Technical indicators also remain weak, with the shares trading below major moving averages and momentum measures such as MACD continuing to signal a negative trend. Valuation metrics offer limited support, as the company remains loss-making and does not currently provide a dividend yield.

More about Bluebird Mining Ventures

Bluebird Mining Ventures Ltd is a London-listed gold streaming, mining and treasury company focused on building a gold-backed treasury through streaming agreements. The company seeks exposure to producing assets across the ore-to-bullion value chain, allowing investors to participate in gold-related cash flows without assuming the capital expenditure requirements and operational risks typically associated with traditional mining operations.

Somero (LSE:SOM) has reported a solid start to 2026, with trading during the first five months of the year performing in line with the full-year expectations outlined in March. The company said activity in its core US private non-residential construction market remains supportive, and management expects to provide a more comprehensive update on first-half performance in July.

The update indicates that demand conditions in the company’s key end markets have remained resilient, helping underpin confidence in its outlook for the remainder of the year.

Board succession plans continue to advance

Alongside its trading update, Somero provided details on ongoing board succession initiatives. The company is continuing its search for an independent non-executive director, with the aim of strengthening board composition and supporting long-term strategic objectives.

Management said the successful candidate will be selected to complement the skills and experience of the existing leadership team while contributing to the creation of sustainable shareholder value.

Governance review could lead to shareholder proposals

The company has also launched a broad review of its governance framework and legal constitution. The assessment will be carried out with support from external advisers and will consider developments in corporate governance standards and best practices.

Depending on the outcome of the review, shareholders may be asked to vote on proposed changes later in the year. The initiative reflects Somero’s intention to ensure its governance arrangements remain aligned with evolving regulatory expectations and the needs of its investor base.

AGM details confirmed

Somero also confirmed arrangements for its upcoming Annual General Meeting, which will take place in Michigan. To encourage wider participation, the meeting will be accessible via webcast, allowing shareholders to follow proceedings remotely.

The company said the hybrid approach is intended to improve engagement and provide investors with greater access to board discussions and key governance matters.

Strong balance sheet offsets operational headwinds

Somero’s outlook continues to benefit from a robust financial position, supported by low leverage levels and healthy cash generation. The company also offers a shareholder-friendly valuation profile, combining a moderate earnings multiple with an attractive dividend yield.

These strengths are partly offset by weaker operating trends in recent years. Revenue has declined over a multi-year period, while margins came under pressure during 2025. Technical indicators also remain subdued, with the shares trading below key moving averages and momentum measures such as MACD remaining negative.

More about Somero Enterprises Inc

Somero Enterprises Inc. operates in the construction equipment industry and specialises in advanced concrete levelling systems and related technologies. The company primarily serves contractors involved in private non-residential construction projects, with the United States representing its largest market. Somero’s equipment is widely used in commercial and industrial developments where high levels of precision and efficiency are required.

Revolution Beauty Group plc (LSE:REVB) has confirmed that the UK Financial Conduct Authority has concluded its investigation into the company and will take no further action against either the business or its founders. The regulatory review, which began in July 2023, has now been formally closed following an earlier decision in late 2024 to discontinue proceedings involving founders Adam Minto and Tom Allsworth.

The conclusion brings an end to a prolonged period of regulatory scrutiny and removes a source of uncertainty that had weighed on the company in recent years.

Governance reforms highlighted following investigation

Chairman Iain McDonald said the company had worked closely with the regulator throughout the process and used the period to strengthen its governance framework and enhance best-practice standards across the business.

Management believes the experience has helped improve oversight and corporate controls, leaving the company better positioned to pursue its long-term objectives. The closure of the investigation also allows leadership to focus fully on operational execution and strategic development without the distraction of ongoing regulatory proceedings.

Founders return as refreshed strategy gains traction

The announcement coincides with the renewed involvement of founders Adam Minto and Tom Allsworth in the business. According to the company, the pair are helping drive a refreshed strategic plan aimed at strengthening the Revolution brand and improving commercial performance.

Management reported encouraging early signs from the updated strategy and expressed confidence that the business is entering a more positive phase following the conclusion of the FCA process. The company believes the combination of enhanced governance and renewed strategic focus could support future growth opportunities.

Financial performance remains the key challenge

Despite the positive regulatory outcome, Revolution Beauty’s outlook continues to be constrained by underlying financial pressures. The company has faced declining revenue, ongoing losses, a significant deterioration in free cash flow and negative shareholder equity, all of which continue to weigh on investor sentiment.

Technical indicators have been more supportive in the short term, reflecting recent share price strength. However, overbought conditions and a weaker longer-term trend reduce the significance of those positive signals. Valuation metrics also offer limited support, as the company’s negative price-to-earnings ratio reflects continued losses rather than an attractive earnings-based valuation.

More about Revolution Beauty Group plc

Revolution Beauty Group plc is a UK-based cosmetics company listed on AIM and focused on the mass-market beauty sector. The group develops, markets and distributes makeup and beauty products under the Revolution brand and related labels, serving value-conscious consumers through a combination of retail partnerships and direct-to-consumer sales channels.